Clinical Stage Cardiovascular Therapeutics Market

The phase I segment leads the clinical stage cardiovascular therapeutics market by phase with a 51.4% share in 2026. Heart failure accounts for 38.1% by indication, small molecules hold 41.7% by modality, and pharma companies represent 48.0% by sponsor.